Adjunctive treatment with eplerenone reduced morbidity and mortality in acute myocardial infarction


QUESTION: In patients with acute myocardial infarction (MI) complicated by left ventricular dysfunction and congestive heart failure (CHF), does adjunctive treatment with eplerenone reduce morbidity and mortality more than placebo?

Design
Randomised (allocation concealed†), blinded (clinicians, patients, outcome assessors, [data collectors, data analysts, and manuscript writers])*, placebo controlled trial with mean 16 months of follow up (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study [EPHESUS]).

Setting
674 centres in 37 countries.

Patients
6642 patients (mean age 64 ± 71% men) with acute MI, left ventricular dysfunction (ejection fraction ≤ 40%), and HF (confirmed by the presence of pulmonary rales, pulmonary venous congestion on chest radiography, or a third heart sound). Exclusion criteria included potassium sparing diuretics, serum creatinine ≥ 220 mmol/L and serum potassium > 5.0 mmol/L before randomisation. 6632 patients (99.8%) were included in the follow up analysis.

Intervention
Patients were stratified by clinical site and allocated 3–14 days after acute MI to eplerenone, 25 mg/day (increased to a maximum of 50 mg/d after 4 wk) (n = 3319) or placebo (n = 3313). All patients received optimal medical treatment (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, diuretics, β blockers, and coronary reperfusion treatment).

Main outcome measures
Time to death from any cause and time to death from cardiovascular (CV) causes or first hospital admission for a CV event (heart failure, recurrent acute MI, stroke, or ventricular arrhythmia). Secondary outcomes were death from CV causes, death from any cause, or any hospital admission.

Main results
Analysis was by intention to treat. Fewer patients in the eplerenone group died from any cause, died from CV causes, or were admitted to hospital for CV events than did those in the placebo group (table). Secondary endpoints were also reduced in eplerenone recipients (table). More patients in the eplerenone group had serious hyperkalaemia (serum potassium concentration ≥ 6.0 mmol/L) than did patients in the placebo group (5.5% vs 3.9%, p = 0.002).

Eplerenone v placebo for myocardial infarction at mean 16 months‡.

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Eplerenone</th>
<th>Placebo</th>
<th>RRR (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death from any cause</td>
<td>14%</td>
<td>17%</td>
<td>15% (4 to 25)</td>
<td>44 (25 to 174)</td>
</tr>
<tr>
<td>Death from CV causes or CV event hospital admission</td>
<td>27%</td>
<td>30%</td>
<td>13% (5 to 21)</td>
<td>31 (19 to 88)</td>
</tr>
<tr>
<td>Death from any cause or any hospital admission</td>
<td>52%</td>
<td>55%</td>
<td>8% (2 to 14)</td>
<td>33 (19 to 147)</td>
</tr>
<tr>
<td>Death from CV causes</td>
<td>12%</td>
<td>15%</td>
<td>17% (6 to 28)</td>
<td>44 (26 to 148)</td>
</tr>
</tbody>
</table>

†CV = cardiovascular. Other abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article.

Conclusion
In patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure, adjunctive treatment with eplerenone reduced morbidity and mortality more than placebo.

COMMENTARY
The results of the EPHESUS study by Pitt et al and the previously published Randomised Aldactone Evaluation Study (RALES)† provide strong evidence for the addition of an aldosterone antagonist to optimal conventional treatment in patients with CHF and reduced left ventricular systolic function.

EPHESUS establishes the role of selective aldosterone antagonism with eplerenone in patients with an EF ≤ 40% and clinical signs of CHF within 3–14 days of an acute MI Debate will probably focus on whether these results are specific to selective aldosterone antagonists (eplerenone) or whether non-selective agents (spironolactone) could provide similar results (particularly if there is a marked price difference).

Are there strong reasons to believe that the potential mechanisms of benefit are unique to eplerenone and not to spironolactone in the postinfarction subgroup of patients with CHF? Probably not. In addition, the magnitude of benefit with spironolactone in the RALES study (in which 5% of patients had an ischaemic basis for CHF) was twice as great in relative terms and 4 times greater in absolute terms than eplerenone in the EPHESUS study. Potential reasons for these differences include the sicker population studied, early termination of the trial, and the short duration of spironolactone use compared to eplerenone.

Although both drugs were well tolerated, a major difference was that men receiving spironolactone had a 10% risk of gynaecomastia or breast pain, which was not seen in men receiving eplerenone.

Overall, the results of the EPHESUS and RALES studies are impressive and warrant the early addition of an aldosterone antagonist (whether eplerenone or spironolactone) for preventing or delaying the considerable mortality and morbidity associated with clinical left ventricular dysfunction caused by MI. These trials also show the need for closer attention to the possibility of hyperkalaemia, particularly in patients with impaired renal function.

Manu Prabhakar, MD
David Massel, MD
London Health Sciences Centre, London, Ontario, Canada